607 related articles for article (PubMed ID: 16075278)
21. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
[TBL] [Abstract][Full Text] [Related]
22. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
[TBL] [Abstract][Full Text] [Related]
23. Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells.
Genovese S; Epifano F; Preziuso F; Slater J; Nangia-Makker P; Majumdar APN; Fiorito S
Biochem Biophys Res Commun; 2020 Jan; 522(1):95-99. PubMed ID: 31740005
[TBL] [Abstract][Full Text] [Related]
24. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Jan; 32(1):53-9. PubMed ID: 22213288
[TBL] [Abstract][Full Text] [Related]
25. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
[TBL] [Abstract][Full Text] [Related]
27. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Bijman MN; Hermelink CA; van Berkel MP; Laan AC; Janmaat ML; Peters GJ; Boven E
Biochem Pharmacol; 2008 Jan; 75(2):427-37. PubMed ID: 17936723
[TBL] [Abstract][Full Text] [Related]
28. [Oxaliplatin: the first DACH platinum in clinical practice].
Soulié P; Raymond E; Brienza S; Cvitkovic E
Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
[TBL] [Abstract][Full Text] [Related]
29. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
31. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
32. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
[TBL] [Abstract][Full Text] [Related]
33. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
34. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
36. Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Raymond E; Djelloul S; Buquet-Fagot C; Mester J; Gespach C
Anticancer Drugs; 1996 Sep; 7(7):752-7. PubMed ID: 8949986
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Plasencia C; Abad A; Martinez-Balibrea E; Taron M
Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
[TBL] [Abstract][Full Text] [Related]
38. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
